Disc Medicine to Present Phase 2 Selcodebart Data in Myelofibrosis Anemia at ASH

By Public Technologies
  • Disc Medicine will present portfolio data at the American Society of Hematology annual meeting in New Orleans, December 12-15, 2026.
  • Clinical updates will include Phase 2 results for selcodebart in myelofibrosis-related anemia and DISC-3405 in polycythemia vera.
  • Initial Phase 1b results for DISC-3405 in sickle cell disease will also be presented.
  • Bitopertin-related preclinical findings showed reduced chronic inflammation and improved red blood cell health in a mouse model of erythropoietic protoporphyria.
  • Published clinical abstracts contain previously presented data; new results and analyses are reserved for the conference.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040905PRIMZONEFULLFEED9869728) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.